Clinical Drug Investigation

, Volume 24, Issue 8, pp 449–455

Daily-Practice Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin in a Large Cohort in Germany

Original Research Article

Abstract

Objective

To monitor the efficacy and safety of moxifloxacin in respiratory tract infections (RTIs) focussing on acute exacerbations of chronic bronchitis (AECB).

Methods

Patients with RTIs could be enrolled in this open-label, prospective, non-controlled post-marketing surveillance study from October 2001 until Junev 2002 unless moxifloxacin was contraindicated. At the initial visit, data were recorded on patient demographics, diagnosis and clinical symptoms. Two follow-up examinations could be performed to determine cure or improvement based on clinical symptoms, and to record adverse events. Clinical symptoms including fever, cough and purulent sputum were assessed individually. Efficacy, tolerability and patient acceptance were assessed globally at the final visit.

Results

Of 9036 enrolled patients, 4328 had AECB, most of whom were treated with moxifloxacin at a daily dose of 400mg. Mean ± SD time to clinical improvement was 3.4 ± 1.5 days, and mean ± SD time to clinical cure was 6.6 ± 2.4 days. Cure rates were 39.4% at day 5 and 94.3% at day 10. By day 6, the proportion of patients with severe cough decreased from 85.4% at the initial visit to 6.9%, and those with severe dyspnoea from 22.5% to 1.2%. Purulent sputum was absent within 4 days in the majority of cases. Physicians rated efficacy, tolerability and patient acceptance as ‘very good’ or ‘good’ in approximately 95% of patients. There were 59 adverse events in 44 (1.0%) patients, most frequently gastrointestinal and nervous system disorders.

Conclusions

This study further confirms that AECB patients treated with moxifloxacin benefit from more rapid symptom relief and that this therapy option is well accepted in general practice.

References

  1. 1.
    Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684–92PubMedCrossRefGoogle Scholar
  2. 2.
    Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; 97 Suppl. C: 3–14CrossRefGoogle Scholar
  3. 3.
    Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbations of chronic bronchitis: results from a German population study. Respir Med 2002; 96: 39–51PubMedCrossRefGoogle Scholar
  4. 4.
    Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22PubMedGoogle Scholar
  5. 5.
    Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358–64PubMedGoogle Scholar
  6. 6.
    Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557–65PubMedCrossRefGoogle Scholar
  7. 7.
    Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015–22PubMedCrossRefGoogle Scholar
  8. 8.
    Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117(5 Suppl. 2): 380–5CrossRefGoogle Scholar
  9. 9.
    Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71PubMedCrossRefGoogle Scholar
  10. 10.
    Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204PubMedGoogle Scholar
  11. 11.
    Grossman R. The value of antibiotics and the outcomes of antibiotic therapy in exacerbation of COPD. Chest 1998; 113(4 Suppl. ): 249–55CrossRefGoogle Scholar
  12. 12.
    Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957–60PubMedCrossRefGoogle Scholar
  13. 13.
    Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 234–47PubMedCrossRefGoogle Scholar
  14. 14.
    Destache CJ. Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002; 22 (1 Pt 2): 12–7CrossRefGoogle Scholar
  15. 15.
    Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone, 2000: 706–710Google Scholar
  16. 16.
    Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antibiotic Surveillance Program, 1997–1999. Clin Infect Dis 2001; 32 Suppl. 2: 81–93CrossRefGoogle Scholar
  17. 17.
    Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341: 1546–8PubMedGoogle Scholar
  18. 18.
    Morrissey I, Colclough A, Viljoen L, et al. The comparative in vitro activity of moxifloxacin against respiratory tract pathogens isolated during 2003 from LIBRA Targeted Surveillance. Clin Microbiol Infect 2004; 10 Suppl. 3: 117–8Google Scholar
  19. 19.
    Blondeau J, Zhao X, Hansen G, et al. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimocrob Agents Chemother 2001; 45: 433–8CrossRefGoogle Scholar
  20. 20.
    Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997–1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462–6PubMedCrossRefGoogle Scholar
  21. 21.
    Jones ME, Karlowsky JA, Blosser-Middleton R, et al. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19: 119–23PubMedCrossRefGoogle Scholar
  22. 22.
    Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002; 46: 522–4PubMedCrossRefGoogle Scholar
  23. 23.
    Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 875–7PubMedCrossRefGoogle Scholar
  24. 24.
    Ackermann G, Schaumann R, Pless B, et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228–32PubMedCrossRefGoogle Scholar
  25. 25.
    Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835–8PubMedCrossRefGoogle Scholar
  26. 26.
    Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 811–8PubMedCrossRefGoogle Scholar
  27. 27.
    Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002; 14 Suppl. 2: 22–8PubMedGoogle Scholar
  28. 28.
    Lorenz J, Busch W, Thate-Waschke I-M, et al. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61–73PubMedGoogle Scholar
  29. 29.
    Lorenz J, Thate-Waschke I-M, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74–86PubMedGoogle Scholar
  30. 30.
    Miravitlles M, Zalacain R, Murio C, et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a twoyear study. Clin Drug Invest 2003; 23(7): 439–50CrossRefGoogle Scholar
  31. 31.
    DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med 2000; l94: 1029–37Google Scholar
  32. 32.
    Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001; 14: 52–9PubMedGoogle Scholar
  33. 33.
    Bauer T, Landen H Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: comparison with prior macrolide treatment. Clin Drug Invest 2002; 22: 641–51CrossRefGoogle Scholar
  34. 34.
    Barth J, Landen H. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. Clin Drug Invest 2003; 23: 1–10CrossRefGoogle Scholar
  35. 35.
    Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501–13PubMedCrossRefGoogle Scholar
  36. 36.
    Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–64. In pressPubMedCrossRefGoogle Scholar
  37. 37.
    Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance [abstract]. Clin Microbiol Infect 2002; 8 Suppl. 1: 323–4Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Kreiskrankenhaus BeeskowBeeskowGermany
  2. 2.Bayer HealthCare PharmaPMS-ManagementLeverkusenGermany

Personalised recommendations